Last €141.79 EUR
Change Today +1.16 / 0.83%
Volume 0.0
J7Z On Other Exchanges
As of 12:55 PM 11/28/14 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

Connaught House

Fourth Floor

One Burlington Road

Dublin, 4


Phone: 353 1 634 7800


Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, focuses on identifying, developing, and commercializing products that address unmet medical needs. Strategy The company’s strategy is to continue to create shareholder value by growing sales of the existing products in its portfolio, including by identifying new growth opportunities; acquiring additional marketed specialty products or products close to regulatory approval to utilize existing expertise and infrastructure; and pursuing targeted development of a pipeline of post-discovery specialty product candidates. Products Xyrem (sodium oxybate) oral solution Xyrem is the treatment approved by the United States Food and Drug Administration (FDA) for both excessive daytime sleepiness (EDS) and cataplexy in patients with narcolepsy. Sodium oxybate, the active pharmaceutical ingredient in Xyrem, is a formulation of the sodium salt of gamma-hydroxybutyrate, an endogenous neurotransmitter and metabolite of gamma-aminobutyric acid. The company promotes Xyrem in the United States through a specialty sales force of approximately 100 sales professionals dedicated to Xyrem. Outside of the United States, the company has licensed to UCB Pharma Limited, or UCB, the exclusive right to market Xyrem for the treatment of narcolepsy in 54 countries in exchange for milestone and royalty payments to it. UCB markets the product in Mexico and 22 countries in Europe. The company has licensed to Valeant Canada Limited, or Valeant, the Canadian marketing rights to Xyrem for the treatment of narcolepsy. The company supplies Xyrem to UCB and Valeant. The company has 14 U.S. patents covering Xyrem, which expire at various times from December 2019 to June 2024. Its issued patents relate to Xyrem’s stable and microbially resistant formulation, its manufacturing process and its method of use, including its restricted distribution system. Erwinaze (asparaginase Erwinia chrysanthemi) Erwinaze, a biologic product, is used in conjunction with chemotherapy to treat patients with ALL who have developed hypersensitivity to E. coli-derived asparaginase. Erwinaze is an asparaginase, a type of enzyme that can deprive leukemic cells of an amino acid essential for their growth. It is derived from a rare bacterium (Erwinia chrysanthemi) and is immunologically distinct from E. coli-derived asparaginase and suitable for patients with hypersensitivity to E. coli-derived treatments. For ALL patients with hypersensitivity to E. coli-derived asparaginase, Erwinaze is a crucial component of their therapeutic regimen. Erwinaze is approved in the United States for administration via intramuscular injection in conjunction with chemotherapy. Erwinaze was originally developed by Public Health England, a U.K. national executive agency, or PHE. Erwinaze was approved by the FDA under a biological license application, or BLA, and was launched in the United States in 2011. Outside of the United States, Erwinaze is sold under the name Erwinase pursuant to marketing authorizations, named patient programs, temporary use authorizations or similar authorizations in multiple countries in Europe and elsewhere. The company promotes Erwinaze in the United States through a specialty sales force. It provides reimbursement support through its JumpStart Access & Reimbursement Solutions program, a dedicated Erwinaze call center. Erwinaze is licensed to the company for worldwide marketing, sales and distribution by PHE, which also manufactures the product for the company. PHE is its sole supplier for Erwinaze. Defitelio (defibrotide) Defibrotide, the active pharmaceutical ingredient in Defitelio, is the sodium salt of a complex mixture of single-stranded oligodeoxyribonucleotides derived from porcine DNA. Defibrotide has been granted orphan drug designation to treat severe veno-occlusive disease (VOD) and to prevent VOD by the FDA, by the European Medicines Agency (EMA) and by the Korean Ministry of Food and Drug Safety. In 2013, the EMA also granted orphan drug designation to defibrotide for the prevention of graft versus host disease (GvHD), another potentially fatal co


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
J7Z:GR €141.79 EUR +1.16

J7Z Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Akorn Inc $40.07 USD +0.89
Alkermes PLC $55.02 USD +0.01
BioMarin Pharmaceutical Inc $89.72 USD +0.34
Sagent Pharmaceuticals Inc $28.83 USD +0.01
Salix Pharmaceuticals Ltd $102.69 USD -0.56
View Industry Companies

Industry Analysis


Industry Average

Valuation J7Z Industry Range
Price/Earnings 100.0x
Price/Sales 9.9x
Price/Book 8.0x
Price/Cash Flow 72.6x
TEV/Sales 8.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JAZZ PHARMACEUTICALS PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at